Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor
Recruiting
- Conditions
- ocally recurrent or metastatic breast cancer patients with HER2/neu negative tumor
- Registration Number
- NL-OMON20125
- Lead Sponsor
- VU University medical centerProf. E. Boven, MD, PhD, medical oncologistDe Boelelaan 11171081 HV AmsterdamPhone: 020-444 4336E-mail: e.boven@vumc.nltogether with:Borstkanker Onderzoek Groep(BOOG) Dr. A.E. van Leeuwen-Stok, research-managerP.O. Box 9236, 1006 AE AmsterdamPhone: 020-346 2547Fax: 020-346 2525E-mail: boog@ikca.nl
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 312
Inclusion Criteria
1. Patients with histologically or cytologically confirmed, HER2/neu-negative, pre- or postmenopausal adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy. Locally recurrent disease must not be amenable to resection and/or radiotherapy with curative intent.
2. Documented ER/PR status
Exclusion Criteria
* Previous treatment
•Previous chemotherapy for locally recurrent or metastatic breast cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method